Table 2.

Correlation of CD68-positiveTAMs in the tumor invasive front with clinicopathological characteristics of intrahepatic cholangiocarcinoma.

Clinicopathological analysis
Variable	high CD68	low CD68	p
No. of patients	42	34
Patient age, years	0.356 ≤ 60	19 (45.2%)	19 (55.9%)
>60	23 (54.8%)	15 (44.1%)
Gender			0.951
Male	17 (40.5%)	14 (41.2%)
Female	25 (59.5%)	20 (58.8%)
Tumor nodules			0.062
Solitary	9 (21.4%)	14 (41.2%)
Multiple	33 (78.6%)	20 (58.8%)
Tumor diameter			0.064
Small	17 (40.5%)	7 (20.6%)
Large	25 (59.5%)	27 (79.4%)
Bilobular hepatic tumor involvement			0.101
Yes	11 (26.2%)	15 (44.1%)
No	31 (73.8%)	19 (55.9%)
Distant metastases			0.111
With	0 (0.00%)	2 (5.9%)
Without	42 (100%)	32 (94.1%)
Angioinvasion			0.197
With	2 (4.8%)	0 (0.00%)
Without	40 (95.2%)	34 (100%)
Lymphangiosis carcinomatosa			0.001
Positive	12 (28.6%)	23 (67.6%)
Negative	30 (71.4%)	11 (32.4%)
Perineural sheath infiltration			0.581
Positive	10 (23.8%)	10 (29.4%)
Negative	32 (76.2%)	24 (70.6%)
Histological differentiation			0.021
Well/moderate	34 (82.9%)	20 (58.8%)
Poor	7 (17.1%)	14 (41.2%)
Pathological T stage			0.001
T1/T2	23 (56.1%)	6 (18.8%)
T3/T4	18 (43.9%)	26 (81.3%)
Pathological N stage			0.744
Positive	15 (35.7%)	13 (39.4%)
Negative	27 (64.3%)	20 (60.6%)
Tumor recurrence			0.004
With	22 (52.4%)	30 (88.2%)
Without	20 (47.6%)	4 (11.8%)
Local recurrence			0.002
With	3 (7.1%)	12 (35.3%)
Without	39 (92.9%)	22 (64.7%)